3 FTSE 100 stocks that could significantly grow my wealth by 2030!

Despite exciting growth prospects, these three FTSE 100 stocks are currently on offer at discounts of up to 33% to their 52-week highs.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The market is no longer feeling the love for a number of FTSE 100 stocks it was recently rating highly. For example, Smith & Nephew (LSE: SN), Hikma Pharmaceuticals (LSE: HIK) and London Stock Exchange Group (LSE: LSEG) are now trading at discounts of up to 33% to their 52-week highs.

I believe they’re quality businesses with excellent long-term prospects. And that the market has overdone its de-rating of them. Today, their shares look very buyable for me and I think they could significantly grow my wealth by 2030.

Road to recovery

Smith & Nephew is a world leader in joint replacement systems for knees, hips and shoulders. Its other specialities are in soft tissue repair and advanced wound management.

The business suffered during the pandemic, due to the postponement of many non-critical surgical operations. There’s a risk that a persistence of delays and of global supply-chain issues could further dent market sentiment towards this FTSE 100 stock. However, I expect management to report an improvement on 2020 in its 2021 results tomorrow. And to guide for a continuing recovery in 2022.

The shares are currently 25% below their 52-week high. They’re rated at 17.5 times consensus forecast earnings for 2022. I think this represents good value for a business that’s nicely aligned with a number of long-term growth drivers, including ageing populations and people’s desire to remain active for longer.

Too cheap to ignore

Rising population and healthcare demand are also long-term tailwinds for Hikma Pharmaceuticals. The company’s portfolio comprises a broad range of branded and non-branded generic medicines. Developing new generics and securing regulatory approval for them can be challenging and protracted. But Hikma’s good record offers me some comfort against this risk.

The business has been more than resilient through the pandemic. It reported 15% growth in earnings in 2020. And I’m expecting further double digit growth when it announces its 2021 results on Thursday. I think a bright outlook statement for 2022 is also on the cards.

The shares are currently 27% off their 52-week high. They’re rated at just 12 times 2022 consensus forecast earnings. Given the momentum in the business and the long-term tailwinds for growth, this FTSE 100 stock looks too cheap for me to ignore.

Transformational acquisition

London Stock Exchange Group transformed itself with the $27bn acquisition of Refinitiv in January last year. Today, it’s not only an exchange operator (a highly attractive business in its own right), but also owns lucrative data and analytics infrastructure at the heart of financial markets.

Initial investor enthusiasm for the deal has waned since it completed. The shares are currently down 33% from their 52-week high. Mega-acquisitions come with risk. And one of those risks — integration costs higher than originally anticipated — soon raised its head.

However, I was encouraged by a trading update in October. Management said it had made good progress on the integration and was comfortably on target for cost synergies ahead of original phasing.

Integration and other acquisition risks haven’t yet been definitively relegated to the rear-view mirror. But priced at 21.5 times 2022 consensus forecast earnings, I think the size of the long-term growth opportunity for the combined businesses makes this another FTSE 100 stock that could significantly increase my wealth by 2030.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals and Smith & Nephew. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

6.9% dividend yield! 2 cheap stocks to consider for a £1,380 passive income

Looking for a market-beating passive income? These FTSE 100 and FTSE 250 dividend stocks could provide a healthy second income…

Read more »

Mature black couple enjoying shopping together in UK high street
Investing Articles

Potentially 34% undervalued, should I be watching the boohoo share price?

The boohoo share price has seen a rocky few years, but with signs that the economy is improving, could this…

Read more »

Investing Articles

Is the Amazon share price primed for a drop?

The Amazon share price has been on a tear for the last year, but can this trend continue? Gordon Best…

Read more »

Photo of a man going through financial problems
Investing Articles

Down 15% in a week! What’s gone wrong with the National Grid share price?

The National Grid share price isn't supposed to crash but now it has. Harvey Jones is wondering whether to take…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

Taylor Wimpey just paid me £158.78. I’m aiming to turn that into a £100k yearly second income

Harvey Jones says small, regular dividend payments can turn a few pounds into a mighty second income, if he gives…

Read more »

A pastel colored growing graph with rising rocket.
Value Shares

These FTSE 250 shares are tipped to rise 14% to 18% in the next year!

Looking for the best FTSE 250 momentum shares to buy? Here are two that City analysts expect to soar in…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

Lloyds’ share price is up 20% in 3 months! How high can it go?

Lloyds’ share price has ripped higher recently. Here, Edward Sheldon provides his view on the level it could potentially climb…

Read more »

Investing Articles

Why the Rolls-Royce share price could continue to outperform

The Rolls-Royce share price keeps moving forward, but this Fool thinks it's still behind where it ought to be after…

Read more »